FDA pushes back release of pharmacogenomics guidance

Share this article:
The FDA has delayed the release of its Guidance for Industry on Pharmacogenomic Data Submissions from today to March 22, according to a Web site report from Genome Web News.
The long-awaited guidance is expected to provide a map for drug developers to step up the science of tailoring drugs to people and ultimately improve drug safety, efficacy and help avoid Vioxx-like withdrawals. Pharmacogenomics uses a DNA test to help doctors decide if a medicine is suitable for a patient.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.